TP53 disruptive mutation predicts platinum-based chemotherapy and PD-1/PD-L1 blockade response in urothelial carcinoma

被引：0
|
作者：
Kaifeng, J. [1 ]
Zewei, W. [1 ]
Zhaopei, L. [2 ]
Jiejie, X. [3 ]
机构：
[1] Fudan Univ, Dept Urol, Zhongshan Hosp, Shanghai, Peoples R China
[2] Fudan Univ, Dept Urol, Shanghai Canc Ctr, Shanghai, Peoples R China
[3] Fudan Univ, Dept Biochem & Mol Biol, Shanghai, Peoples R China
来源：
EUROPEAN UROLOGY | 2024年 / 85卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
A0757
引用
收藏
页码：S1737 / S1738
页数：2
相关论文
共 50 条
  • [31] Evaluation of PD-1 and PD-L1 expression in canine urothelial carcinoma cell lines
    Pinard, Christopher J.
    Hocker, Samuel E.
    Poon, Andrew C.
    Inkol, Jordon M.
    Matsuyama, Arata
    Wood, R. Darren
    Wood, Geoffrey A.
    Woods, J. Paul
    Mutsaers, Anthony J.
    VETERINARY IMMUNOLOGY AND IMMUNOPATHOLOGY, 2022, 243
  • [32] Prognostic value of PD-1/PD-L1 expression in upper tract urothelial carcinoma
    Campedel, L.
    Seisen, T.
    Cussenot, O.
    Comperat, E.
    Varinot, J.
    Roupret, M.
    Cancel-Tassin, G.
    PROGRES EN UROLOGIE, 2018, 28 (16): : 900 - 905
  • [33] Research progress on PD-1 and PD-L1 inhibitors in the treatment of metastatic urothelial carcinoma
    Tang, Quanqing
    Li, Shihao
    Huang, Gaozhen
    Liu, Hongwei
    INTERNATIONAL IMMUNOPHARMACOLOGY, 2023, 119
  • [34] Basal cell carcinoma: PD-L1/PD-1 checkpoint expression and tumor regression after PD-1 blockade
    Lipson, Evan J.
    Lilo, Mohammed T.
    Ogurtsova, Aleksandra
    Esandrio, Jessica
    Xu, Haiying
    Brothers, Patricia
    Schollenberger, Megan
    Sharfman, William H.
    Taube, Janis M.
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2017, 5
  • [35] PD-1/PD-L1 blockade in renal cell cancer
    Beckermann, Kathryn E.
    Johnson, Douglas B.
    Sosman, Jeffrey A.
    EXPERT REVIEW OF CLINICAL IMMUNOLOGY, 2017, 13 (01) : 77 - 84
  • [36] Development of cancer immunotherapy based on PD-1/PD-L1 pathway blockade
    Zhang, Min
    Liu, Kehai
    Wang, Mingfu
    RSC ADVANCES, 2019, 9 (58) : 33903 - 33911
  • [37] Biomarkers of response to PD-1/PD-L1 inhibition
    Vareki, Saman Maleki
    Garrigos, Carmen
    Duran, Ignacio
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2017, 116 : 116 - 124
  • [38] Chemotherapy + PD-1/PD-L1 Blockade Should Be the Preferred Option in the Neoadjuvant Therapy of NSCLC
    Rosner, Samuel
    Forde, Patrick M.
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (04) : 503 - 509
  • [39] PD-L1 Expression in Mucosal Malignant Melanoma: Implications for PD-1/PD-L1 Blockade Therapy
    Lilo, Mohammed
    Berry, Sneha
    Xu, Haiying
    Ogurtsova, Aleksandra
    Lipson, Evan
    Taube, Janis
    MODERN PATHOLOGY, 2015, 28 : 123A - 123A
  • [40] The MHC-I-dependent neoantigen presentation pathway predicts response rate to PD-1/PD-L1 blockade
    Zhang, Yuchen
    Yang, Chen
    Xu, Yanchao
    Jiang, Xiang
    Shi, Jiajun
    Li, Binghua
    Yu, Decai
    BIOMOLECULES AND BIOMEDICINE, 2024,
12345